NCT03706261View on ClinicalTrials.gov

Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

March 22, 2019

Primary Completion Date

July 14, 2023

Study Completion Date

July 14, 2023

Conditions
Alzheimer Disease
Interventions
DRUG

18F-MK-6240

Administration of 5 mCi of 18F-MK-6240 for tau PET.

DRUG

18F-Florbetaben

Administration of 8.1 mCi as a slow single intravenous bolus (6 sec/mL) in a total volume of up to 10 mL of 18F-Florbetaben for Aβ PET imaging.

Trial Locations (1)

10032

Columbia University Irving Medical Center, New York

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Adam Brickman

OTHER

NCT03706261 - Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults | Biotech Hunter | Biotech Hunter